PolyNovo Limited

PolyNovo Limited Earnings Recaps

PNV.AX Health Care 1 recap
Next earnings: March 2, 2027 (estimated) · full calendar
Q2 2026 Feb 20, 2026

PolyNovo demonstrated strong financial performance in the first half of FY '26, with sales rising 26% year-on-year to $68.2 million, driven primarily by robust growth in the U.S. market.

Key takeaways
  • U.S. sales reached $51.7 million, marking a 25.4% increase, underscoring continued market penetration and operational execution.
  • The company's APAC region excelled, expanding beyond traditional burn applications, contributing to its global growth narrative.
  • PolyNovo is finalizing a PMA submission for NovoSorb BTM, which is expected to enhance its market position in the U.S. and access additional markets like Japan and China.
  • The management transition has strengthened the leadership team, with a focus on enhancing market access, particularly in outpatient settings.
  • The upcoming launch of the MTX product and new distribution partnerships are expected to further accelerate growth momentum across multiple geographies.